Core Insights - 22nd Century Group, Inc. is launching new Pinnacle VLN and moist snuff products in over 1,700 stores across 27 states, marking a significant expansion in its product offerings [1][2] - The new products include Pinnacle VLN Gold and Menthol VLN cigarettes, which are expected to begin sales in late summer and early fall of 2025 [2][4] - The company aims to leverage its established Pinnacle brand, which has a strong sales track record, to drive success in the new product categories [2][5] Product Launch Details - The launch includes four new Pinnacle SKUs, with two specifically in the low nicotine category [1] - The moist snuff products will feature straight and wintergreen flavors, expected to be available in the second half of 2025 [4] - The manufacturing of these products will utilize proprietary VLN tobacco strains and will be distributed through existing national-scale distribution agreements [5][6] Company Background - 22nd Century Group is recognized as a pioneering nicotine harm reduction company, focusing on enabling smokers to control their nicotine consumption [7] - The flagship VLN cigarette contains 95% less nicotine than traditional cigarettes, providing an alternative for smokers looking to reduce their nicotine intake [8][10] - The company operates a facility in Mocksville, North Carolina, with the capacity to produce over 45 million cartons of combustible tobacco products annually [9]

Group 1 - Nestle SA is one of 178 companies in the Consumer Staples group, currently ranked 15 within the Zacks Sector Rank [2] - The Zacks Rank for Nestle SA is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] - The Zacks Consensus Estimate for Nestle SA's full-year earnings has increased by 5.6% in the past quarter, reflecting improved analyst sentiment [4] Group 2 - Nestle SA has gained approximately 21.7% year-to-date, outperforming the Consumer Staples sector, which has returned an average of 5.1% [4] - In contrast, Philip Morris, another stock in the Consumer Staples sector, has achieved a year-to-date return of 52.3% [5] - Nestle SA belongs to the Consumer Products - Staples industry, which has lost an average of 3% this year, indicating that Nestle SA is performing better than its industry [6] Group 3 - The Tobacco industry, which includes Philip Morris, is currently ranked 44 and has increased by 40.4% this year [6] - Investors should continue to monitor both Nestle SA and Philip Morris for potential sustained performance in the Consumer Staples sector [7]

Core Viewpoint - The resurgence of tobacco stocks, particularly Altria Group, has been notable in 2025, with shares up nearly 17% and approaching $60, a level not seen since 2017, as investors seek safe-haven stocks during uncertain times [1]. Company Overview - Altria Group, owner of the Marlboro brand, primarily operates in the U.S. market and has faced significant declines in cigarette usage, which is expected to continue, particularly among young adults [3][8]. - The company has invested in diversifying its product offerings, including cannabis, nicotine pouches, cigars, electronic vaping, and alcohol, but has experienced muted success and notable failures, such as the $12.8 billion investment in Juul, which was written down to zero [4][12]. Financial Performance - The majority of Altria's revenue, approximately 88%, still comes from smokables, with new initiatives in vaping and nicotine pouches contributing minimally to overall revenue [5]. - Cigarette volumes for Marlboro declined by 13.3% year-over-year, a significant acceleration compared to historical declines of under 5% annually, indicating a major shift in the industry [8][10]. Dividend and Profitability Risks - Altria's ability to maintain profits has relied on increasing cigarette prices and reducing overhead costs, but this strategy is not sustainable long-term as the majority of its $11.6 billion in annual operating earnings is derived from cigarettes [9][10]. - The company faces risks to its dividend growth, which could be halted or slashed if profits decline without being replaced by new nicotine consumption [9][10]. Debt and Financial Strategy - Altria has accumulated $26 billion in debt, primarily to fund stock repurchases, which has not yet led to a dividend cut but poses risks for the future as the cigarette business deteriorates [14]. - The company has reduced its shares outstanding by about 10% over the last five years, which can benefit dividend per share but is being achieved through increased leverage [13][14]. Investment Outlook - The combination of a highly leveraged balance sheet, significant volume declines, and lack of successful diversification presents a challenging outlook for Altria Group, suggesting that investors should be cautious about purchasing the stock even with its attractive dividend yield [15][16].

Core Viewpoint - The U.S. Supreme Court ruled that individuals adversely affected by FDA orders can challenge the agency in court, affirming the right of retailers to contest FDA decisions that impact their sales [1][2][3]. Group 1: Legal Context - Under the Family Smoking Prevention and Tobacco Control Act (TCA), manufacturers must obtain FDA approval to sell certain vaping products, such as R.J. Reynolds' "Vuse" e-cigarettes [2]. - The FDA denied R.J. Reynolds' application, which led to a ban on the sale of Vuse e-cigarettes by retailers who were previously allowed to sell them while the application was pending [2]. - Retailers argued that the FDA's decision adversely affected them by resulting in lost sales, leading to a petition for review in the U.S. Court of Appeals for the Fifth Circuit [2]. Group 2: Court Rulings - The Fifth Circuit ruled that retailers have standing to challenge the FDA's decision, rejecting the FDA's argument that only the manufacturer could be considered "adversely affected" under the TCA [2]. - The Supreme Court affirmed the Fifth Circuit's judgment, reinforcing the broad interpretation of "adversely affected" as it relates to judicial review of agency actions [3]. Group 3: Implications of the Ruling - The ruling prevents the FDA from narrowing the scope of judicial review provisions under the TCA and other statutes, allowing those harmed by agency actions to seek relief in federal court [3]. - The decision is seen as a significant affirmation of the ability for individuals and entities to challenge federal regulations, even if they were not directly involved in the agency's decision-making process [4].

Key Takeaways Stocks making new highs tend to make even higher highs. Both PM and STRL shares have benefited from strong quarterly results. Both companies' near-term outlooks allude to further gains. When stocks are cruising near all-time or 52-week highs, it reflects considerable bullishness with trends where buyers are in control. Stocks making new highs tend to make even higher highs, particularly when analysts' positive earnings estimate revisions are present.   That’s been precisely the case for Phil ...

Iqos logo is seen at the store in Warsaw, Poland on November 13, 2024. (Photo by Jakub ... More Porzycki/NurPhoto via Getty Images)NurPhoto via Getty ImagesQuestion: Why would you pay 37 times earnings for Philip Morris stock when you can buy Google stock for a much cheaper valuation of 19 times earnings? You wouldn’t, especially when you consider three simple facts: Growth: Google’s revenue growth rate is accelerating at over 13% - better than Philip Morris’s revenue growth of 7%. Over the last three years ...

Market Overview - U.S. stock markets experienced significant volatility in the first half of 2025, contrasting with the smooth rally of the previous two years, primarily due to tariffs imposed by the Trump administration, inflation fears, and concerns over U.S. AI companies [1] - Recent positive developments in global tariffs, a declining inflation rate, and favorable economic data have led to a recovery in Wall Street, alleviating recession fears [2] Geopolitical Factors - The U.S.-China trade deal remains unfinalized, contributing to ongoing market fluctuations, alongside geopolitical tensions in the Middle East and the prolonged conflict between Russia and Ukraine [3] Consumer Staples Sector - The consumer staples sector is characterized as mature and fundamentally strong, with demand for essential products being relatively immune to economic cycles, making it a defensive investment choice [5][6] - This sector is known for stable earnings and cash flows, providing a safe haven for investors during market volatility [6] Recommended Stocks - Investment in defensive stocks like consumer staples is advised to stabilize portfolios, with five high-dividend paying stocks recommended: Philip Morris International Inc. (PM), The Coca-Cola Co. (KO), Mondelez International Inc. (MDLZ), Altria Group Inc. (MO), and Corteva Inc. (CTVA) [4] Company Performance Philip Morris International Inc. (PM) - PM anticipates 2025 volume growth, with smoke-free products projected to rise by 12-14%, aiming for substantial smoke-free status by 2030 [10][11][12] - Expected revenue and earnings growth rates for PM are 8.1% and 13.7%, respectively, with a current dividend yield of 2.94% [13] The Coca-Cola Co. (KO) - Coca-Cola reported its ninth consecutive earnings beat in Q1 2025, driven by broad-based growth and effective execution of its all-weather strategy [14][15] - Expected revenue and earnings growth rates for KO are 2.5% and 3.1%, respectively, with a current dividend yield of 2.93% [15] Mondelez International Inc. (MDLZ) - Mondelez achieved 3.1% organic revenue growth in Q1 2025, supported by strategic pricing and strong performance in core categories [16][17] - Expected revenue and earnings growth rates for MDLZ are 5.3% and -10.1%, respectively, with a current dividend yield of 2.83% [18] Altria Group Inc. (MO) - Altria's first-quarter results were bolstered by pricing power despite weaker volumes, particularly in the smokeable product unit [19][20] - Expected revenue and earnings growth rates for MO are -1.4% and 5.3%, respectively, with a current dividend yield of 6.92% [21] Corteva Inc. (CTVA) - Corteva operates in agriculture, focusing on seed development and crop protection, with operations across multiple regions [22][23][24] - Expected revenue and earnings growth rates for CTVA are 2.5% and 16.3%, respectively, with a current dividend yield of 0.92% [25]

Key Takeaways MO trades at a forward P/E of 10.81, well below industry peers and the broader market average. Altria's on! shipments rose 18% in Q1, gaining share in oral tobacco and nicotine pouch categories. EPS estimates for MO have been revised upward, with 2025 growth projected at 5.3% year over year.Altria Group, Inc. (MO) is currently trading at an attractive discount compared to its industry peers and the broader market, making it a potential value pick for long-term investors. MO stock trades at a ...

Core Insights - Altria Group, Inc. is facing significant challenges as it transitions towards smoke-free alternatives, primarily due to the rise of illicit flavored disposable e-vapor products that are reshaping the U.S. nicotine market [1][3]. Company Performance - In Q1 2025, Altria reported that the adult e-vapor user base in the U.S. has exceeded 20 million, with a year-over-year increase of over 2.6 million users, largely driven by disposable e-vapor products which gained nearly 4 million new users, reaching around 14 million [2]. - Altria estimates that over 60% of the expanding e-vapor market is now dominated by unauthorized, non-compliant products, which poses a significant challenge to its smoke-free revenue growth [2][10]. Market Dynamics - The surge in illicit e-vapor products is a major obstacle for Altria's smoke-free revenue growth, dampening its progress despite an increasing market presence [3]. - The company is collaborating with regulators to address enforcement gaps, but the ongoing availability of illicit products remains a significant barrier [4]. Competitive Landscape - Major tobacco companies like Philip Morris International and British American Tobacco are also accelerating their transition towards smoke-free alternatives, investing in reduced-risk products to adapt to changing consumer preferences and regulatory landscapes [6]. - Philip Morris reported that smoke-free offerings contributed 44% of its gross profit in Q1 2025, with a 20.4% rise in net revenues and a 33.1% increase in smoke-free gross profit [7]. - British American Tobacco aims to reach 50 million consumers by 2030, with its smokeless user base reaching 29.1 million in 2024 [8]. Financial Metrics - Altria's shares have gained 14.4% year-to-date, compared to the industry's growth of 40.8% [9]. - The company trades at a forward price-to-earnings ratio of 10.96X, below the industry average of 15.74X, with a forecasted EPS growth of 5.3% for 2025 [10][12]. - The Zacks Consensus Estimate for Altria's 2025 earnings implies a year-over-year growth of 5.3%, while the 2026 earnings estimate suggests an increase of almost 3% [13].

Market Overview - The U.S. stock market is expected to experience volatility due to rising tensions between Israel and Iran, which have led to increased oil prices and concerns about a broader regional conflict [1] - Uncertainty surrounding the Federal Reserve's interest rate decisions amid these geopolitical risks is adding further pressure to the market [1] Investment Strategy - A curated portfolio of low-beta stocks is recommended as a strategy to navigate the uncertain market conditions [2] - Low-beta stocks such as VirTra Inc. (VTSI), Franco-Nevada Corporation (FNV), Elbit Systems Ltd (ESLT), and Philip Morris International Inc. (PM) are highlighted as potential investment opportunities [2] Stock Characteristics - Beta is a measure of a stock's volatility compared to the market, with a beta of 1 indicating movement in line with the market, greater than 1 indicating higher volatility, and less than 1 indicating lower volatility [3][4] - Stocks with a beta between 0 and 0.6 are screened for lower volatility, alongside other criteria such as positive price movement over the last month, average trading volume greater than 50,000, a price of at least $5, and a Zacks Rank of 1 (Strong Buy) [5][6] Company Insights - **VirTra Inc. (VTSI)**: The company is benefiting from the U.S. Army's Integrated Visual Augmentation System (IVAS) project, which enhances training for soldiers and positions VirTra favorably for military contracts [7][9] - **Franco-Nevada Corporation (FNV)**: Recently invested $1.05 billion in a royalty on the Côté Gold Mine, which is expected to close by Q2 2025, indicating strong revenue potential from significant gold resources [9][10] - **Elbit Systems Ltd (ESLT)**: The company has a substantial backlog of $23.1 billion, with 66% of its contracts coming from international markets, reflecting strong global demand for defense solutions [9][11] - **Philip Morris International Inc. (PM)**: Transitioning from traditional cigarettes to smoke-free products like IQOS and ZYN, while focusing on shareholder returns and cost-cutting measures [12]